FDA approved the Company’s first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales force
New
Management to host conference call and webcast today,
The third quarter and the weeks since mark NRx’s transition from a development-stage company to a commercial one, led by FDA approval of the Company’s first drug, preservative-free ketamine.
Key recent and third quarter highlights include:
- FDA approval of preservative-free ketamine: On
October 2026 , theU.S. Food and Drug Administration (FDA) approved the Company’s Abbreviated New Drug Application (ANDA) for preservative-free ketamine, ahead of theNovember 10, 2026 GDUFA goal date. This is NRx’s first drug approval and, to the Company’s knowledge, the first FDA approval of a blow-fill-seal (BFS) vial with a luer-lock connection as a drug/device combination. - Commercial launch: NRx began selling preservative-free ketamine the week of
November 9 with a 17-person sales force calling on hospitals and group purchasing organizations. The Company has received its first order and product shipments are scheduled to begin no later thanJanuary 2027 . - Sterile injectable product opportunity: The company expects the initial market for preservative free ketamine to be approximately
$400M in the US, growing at 15% per year. The company intends to add additional already approved sterile products that could double this market opportunity in 2027. - NRX-100 and Yale collaboration: Signed a collaboration agreement with
Yale University , with the written approval of thePatient-Centered Outcomes Research Institute (PCORI), for NRx to join as a sponsor of a newly launched five-yearPCORI study comparing IV ketamine with intranasal S-ketamine. The Company believes this study can provide the confirmatory evidence required under FDA’s Accelerated Approval pathway. NRx aims to submit a rolling New Drug Application (NDA) for NRX-100 by the end of 2026. - New pipeline product, NRX-200: Announced NRX-200, a proprietary, neutral-pH formulation of ketamine based on an already FDA-approved cyclodextrin vehicle, designed for subcutaneous delivery by infusion pump. Pharmacokinetic testing is expected to begin in early 2027, with a first-in-human trial targeted for
September 2027 . DARPA prime contract: InOctober 2026 , theDefense Advanced Research Projects Agency (DARPA) awarded NRx Defense Systems an$11.25 million prime contract to lead SPARC-TMS (NCT07227103), a Phase 3 trial of NRX-101 with rapid, robotic Transcranial Magnetic Stimulation (TMS).DARPA has approved the first two invoices for payment in the fourth quarter of 2026.- HOPE Therapeutics: Operates six locations in
Florida and is treating patients with robotic, neuronavigated TMS in partnership withZeta Surgical . GeNeuro :GeNeuro plans to initiate clinical trials in ALS and schizophrenia in the second half of 2027, with support from the US, French, and Swiss governments.- Balance sheet: Ended the quarter with
$19.8 million in cash and cash equivalents and no convertible debt.
The approved product is packaged in a BFS vial with a luer-lock connection, developed with
“The third quarter and the weeks since have marked NRx’s transition from a development-stage company to a commercial one,” said Dr.
Financial Results for the Quarter Ended
For the third quarter of 2026, net patient service revenue was
Loss from operations for the third quarter of 2026 was
Net loss for the third quarter of 2026 was
For the nine months ended
As of
Conference Call Details
NRx will host a conference call and webcast today,
Domestic: 1-800-717-1738
International: +1-646-307-1865
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a commercial-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company has been awarded an Abbreviated New Drug Approval (ANDA) for Preservative-Free Ketamine and is seeking New Drug Approval for a presentation of intravenous ketamine (NRX-100) with approved claims for treating depression and suicidality.
In October 2026 the Defense Advanced Research Projects Agency awarded an $11.25 million contract to NRx to conduct a phase 3 trial of its oral drug NRX-101, (D-cycloserine/lurasidone) combined with Robotic Neuronavigated Transcranial Magnetic Stimulation as a one-day treatment for patients with depression. NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Brian Korb
Managing Partner
astr partners
(917) 653-5122
brian.korb@astrpartners.com
Media Contact:
Victoria Verdeja
RXMD
(305) 904-1038
vverdeja@rxmedyn.com
Source: NRx Pharmaceuticals, Inc.
